

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50111/043002
	Serial No.	09/215,163
	Applicant	Stinson et al.
	Filing Date	December 18, 1998
	Group	1645
	IDS Filed	May 30, 2007

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Campbell, "Chapter 10: Characterisation of monoclonal antibodies," <i>Laboratory Techniques in Biochemistry and Molecular Biology</i> . Elsevier Science Publishers B.V. Vol. 3, pp. 186-187 (1984).
	Dowling et al., "Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody α Sb2 administered intravenously to healthy adult volunteers," <i>Antimicrob. Agents Chemother.</i> 49:1808-1812 (2005).
	Islam et al., "Production and characterization of monoclonal antibodies with therapeutic potential against Shiga toxin," <i>J. Clin. Lab. Immunol.</i> 33:11-16 (1990).
	Simon et al., "Shiga toxin 1 elicits diverse biologic responses in mesangial cells," <i>Kidney Int.</i> 54:1117-1127 (1998).
	Smith et al., "Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2," <i>Vaccine</i> 24:4122-4129 (2006).
	Wen et al., "Genetic toxoids of shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge," <i>Vaccine</i> 24:1142-1148 (2006).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	